These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16528749)

  • 1. [18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studies.
    Racette BA; Good L; Antenor JA; McGee-Minnich L; Moerlein SM; Videen TO; Perlmutter JS
    Am J Med Genet B Neuropsychiatr Genet; 2006 Apr; 141B(3):245-9. PubMed ID: 16528749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.
    Gallagher CL; Oakes TR; Johnson SC; Chung MK; Holden JE; Bendlin BB; McLaren DG; Xu G; Nickles RJ; Pyzalski R; DeJesus O; Brown WD
    Mov Disord; 2011 Mar; 26(4):614-20. PubMed ID: 21449008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-incident, Old-Order Amish family with PD.
    Racette BA; Rundle M; Wang JC; Goate A; Saccone NL; Farrer M; Lincoln S; Hussey J; Smemo S; Lin J; Suarez B; Parsian A; Perlmutter JS
    Neurology; 2002 Feb; 58(4):568-74. PubMed ID: 11865134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
    Thobois S; Guillouet S; Broussolle E
    Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
    Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
    Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.
    Eidelberg D; Moeller JR; Dhawan V; Sidtis JJ; Ginos JZ; Strother SC; Cedarbaum J; Greene P; Fahn S; Rottenberg DA
    Mov Disord; 1990; 5(3):203-13. PubMed ID: 2117706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
    Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
    J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PET study using 6-[18F]-fluorodopa in Parkinson's disease].
    Nagasawa H; Tanji H; Itoh M; Itoyama Y
    Nihon Rinsho; 1997 Jan; 55(1):213-7. PubMed ID: 9014452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
    Nurmi E; Ruottinen HM; Bergman J; Haaparanta M; Solin O; Sonninen P; Rinne JO
    Mov Disord; 2001 Jul; 16(4):608-15. PubMed ID: 11481683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.
    Kaasinen V; Maguire RP; Hundemer HP; Leenders KL
    J Neurol; 2006 Mar; 253(3):340-8. PubMed ID: 16222426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
    Dhawan V; Ishikawa T; Patlak C; Chaly T; Robeson W; Belakhlef A; Margouleff C; Mandel F; Eidelberg D
    J Nucl Med; 1996 Feb; 37(2):209-16. PubMed ID: 8667046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A revisit to quantitative PET with
    Akamatsu G; Ohnishi A; Aita K; Nishida H; Ikari Y; Sasaki M; Kohara N; Senda M
    Ann Nucl Med; 2017 Feb; 31(2):163-171. PubMed ID: 27914043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased pineal Fdopa uptake is related to severity of Parkinson's disease--a PET study.
    Ghaemi M; Rudolf J; Hilker R; Herholz K; Heiss WD
    J Pineal Res; 2001 May; 30(4):213-9. PubMed ID: 11339510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET.
    Huang WS; Ma KH; Chou YH; Chen CY; Liu RS; Liu JC
    Nucl Med Commun; 2003 Jan; 24(1):77-83. PubMed ID: 12501023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
    Lizarraga KJ; Allen-Auerbach M; Czernin J; DeSalles AA; Yong WH; Phelps ME; Chen W
    J Nucl Med; 2014 Jan; 55(1):30-6. PubMed ID: 24167081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity.
    Kumakura Y; Vernaleken I; Gründer G; Bartenstein P; Gjedde A; Cumming P
    J Cereb Blood Flow Metab; 2005 Jul; 25(7):807-19. PubMed ID: 15729292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.